Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: BLFS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.3
1 Year Target Price $31.3
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.93% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio - | 1Y Target Price 31.3 |
Price to earnings Ratio - | 1Y Target Price 31.3 | ||
Volume (30-day avg) 9 | Beta 1.78 | 52 Weeks Range 19.10 - 29.55 | Updated Date 09/16/2025 |
52 Weeks Range 19.10 - 29.55 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.92% | Operating Margin (TTM) -4.41% |
Management Effectiveness
Return on Assets (TTM) -0.8% | Return on Equity (TTM) -5.66% |
Valuation
Trailing PE - | Forward PE 285.71 | Enterprise Value 1164112310 | Price to Sales(TTM) 13.22 |
Enterprise Value 1164112310 | Price to Sales(TTM) 13.22 | ||
Enterprise Value to Revenue 12.45 | Enterprise Value to EBITDA 66.75 | Shares Outstanding 47905300 | Shares Floating 39409745 |
Shares Outstanding 47905300 | Shares Floating 39409745 | ||
Percent Insiders 2.11 | Percent Institutions 104.51 |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions, Inc. was founded in 1997. It focuses on developing, manufacturing, and marketing biopreservation media for cells, tissues, and organs. The company has grown through organic expansion and acquisitions to support the cell and gene therapy markets.
Core Business Areas
- Biopreservation Media: Development and distribution of proprietary biopreservation media products, including CryoStor and HypoThermosol, used to preserve cells and tissues during freezing and thawing processes.
- Cell Processing: Offerings related to cell thawing, washing, and concentration, supporting the overall cell processing workflow.
- Storage and Cold Chain: Provides freezers, cloud-based inventory management system (SAVAS), and related services to manage the storage and transport of biological materials, and liquid nitrogen storage.
Leadership and Structure
Mike Rice is the CEO. The company has a typical corporate structure with departments such as R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- CryoStor: A line of cryopreservation media products designed to optimize the preservation of cells during freezing. CryoStor is a leader in this space, with a significant market share in the cell and gene therapy market. Competitors include STEMCELL Technologies and Corning. Revenue is difficult to estimate directly, but it is a primary revenue driver.
- HypoThermosol: A hypothermic storage and shipping media designed to preserve cells at refrigerated temperatures. It is used for short-term storage and transport of cells and tissues. Main competitor is STEMCELL Technologies, and the revenue is a key driver to BioLife Solutions.
- SAVAS: A cloud-based inventory management system for biological materials. Revenue driver.
Market Dynamics
Industry Overview
The biopreservation market is growing rapidly, driven by the expansion of cell and gene therapies, regenerative medicine, and personalized medicine. The industry is characterized by high barriers to entry due to regulatory requirements and the need for specialized expertise.
Positioning
BioLife Solutions is a leading provider of biopreservation tools and services, particularly in the cell and gene therapy space. Its competitive advantages include its established product portfolio, strong brand recognition, and focus on innovation.
Total Addressable Market (TAM)
The total addressable market (TAM) for biopreservation solutions is estimated to be in the billions of dollars and the cell and gene therapy market are expanding rapidly. BioLife Solutions is well positioned to capture a significant share of this market due to its established presence, product portfolio, and focus on innovation.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Established product portfolio
- Focus on innovation
- Leading position in cell and gene therapy biopreservation
Weaknesses
- Dependence on the growth of cell and gene therapies
- Potential for increased competition
- Fluctuations in gross margin
- Cost of Revenue issues.
Opportunities
- Expansion into new geographic markets
- Development of new biopreservation products
- Acquisitions of complementary businesses
- Growth in regenerative medicine
Threats
- Regulatory changes
- Economic downturns
- Technological obsolescence
- Increased competition
Competitors and Market Share
Key Competitors
- STEM
- CCRD
- LON:SHC
Competitive Landscape
BioLife Solutions has a strong position in the biopreservation market, particularly in cell and gene therapy. Competitors include companies offering similar biopreservation media and those providing alternative cell processing and storage solutions. BioLife's advantage lies in its specialized product portfolio and focus on the cell and gene therapy sector.
Major Acquisitions
SAVAS Biologics
- Year: 2021
- Acquisition Price (USD millions): 85
- Strategic Rationale: Enhanced BioLife Solutions' portfolio of tools and services for cell and gene therapy.
Growth Trajectory and Initiatives
Historical Growth: BioLife Solutions has experienced significant revenue growth in recent years, driven by the expansion of cell and gene therapies and strategic acquisitions.
Future Projections: Future growth projections depend on the continued expansion of the cell and gene therapy market, new product development, and successful acquisitions. Analyst estimates vary.
Recent Initiatives: Recent initiatives include acquisitions of companies to expand its product offerings and market reach, and investments in research and development to develop new biopreservation technologies.
Summary
BioLife Solutions is a key player in the biopreservation market, particularly for cell and gene therapies. Its strategic acquisitions, strong product portfolio, and innovative focus position it for continued growth. However, dependence on the cell and gene therapy market and increasing competition pose challenges. Overall, the company is showing strength and innovation in their growing segment of the industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Investor Relations Materials
- Third-Party Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data and analyst estimates are subject to change and may not be accurate. It is recommended to consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.